Disease-modifying treatment in progressive multiple sclerosis
JR Ciotti, AH Cross - Current treatment options in neurology, 2018 - Springer
Purpose of review Multiple sclerosis (MS) is an immune-mediated disorder that affects the
central nervous system (CNS), often first affecting people in early adulthood. Although most …
central nervous system (CNS), often first affecting people in early adulthood. Although most …
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives
A Gajofatto, M Turatti, MD Benedetti - Expert review of …, 2017 - Taylor & Francis
Introduction: Multiple sclerosis (MS) is a chronic inflammatory condition of the central
nervous system with heterogeneous features. Primary progressive (PP) MS is a rare disease …
nervous system with heterogeneous features. Primary progressive (PP) MS is a rare disease …
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis–a review of population-specific evidence from randomized clinical trials
A Bayas, M Christ, S Faissner… - Therapeutic …, 2023 - journals.sagepub.com
Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving,
early detection of relapse-independent progression remains difficult. This is further …
early detection of relapse-independent progression remains difficult. This is further …
[HTML][HTML] Primary progressive multiple sclerosis: putting together the puzzle
A Abdelhak, MS Weber, H Tumani - Frontiers in neurology, 2017 - frontiersin.org
The focus of multiple sclerosis research has recently turned to the relatively rare and clearly
more challenging condition of primary progressive multiple sclerosis (PPMS). Many risk …
more challenging condition of primary progressive multiple sclerosis (PPMS). Many risk …
Ocrelizumab: a new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis
AM Stahnke, KM Holt - Annals of Pharmacotherapy, 2018 - journals.sagepub.com
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of
ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS). Data Sources: A …
ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS). Data Sources: A …
[HTML][HTML] Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
R McCool, K Wilson, M Arber, K Fleetwood… - Multiple sclerosis and …, 2019 - Elsevier
Background Ocrelizumab was approved for the treatment of relapsing multiple sclerosis
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …
Progressive multiple sclerosis
D Ontaneda, RJ Fox - Current opinion in neurology, 2015 - journals.lww.com
PMS represents a significant challenge, as the pathogenesis of the disease is not well
understood, no validated outcome metrics have been established and clinical trial …
understood, no validated outcome metrics have been established and clinical trial …
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
B Weinstock-Guttman, R Bermel… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Background: Many patients with multiple sclerosis (MS) experience suboptimal disease
control despite the use of disease-modifying therapy (DMT). Objective: To assess the …
control despite the use of disease-modifying therapy (DMT). Objective: To assess the …
[HTML][HTML] Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension
Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-
modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase …
modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase …
Effectiveness of ocrelizumab in primary progressive multiple sclerosis: a multicenter, retrospective, real-world study (OPPORTUNITY)
Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-
expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis …
expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis …